For providers
Oncodetect™ Molecular Residual Disease test

Make circulating tumor DNA stand out among cell-free DNA

The Oncodetect Molecular Residual Disease (MRD) test quantifies and monitors levels of circulating tumor DNA (ctDNA) in the blood. The results can help you make more personalized treatment decisions regarding adjuvant therapy, cancer recurrence, and response to treatment.
Dark gray DNA helixes with an orange circle around one gold helix, and the words ‘For solid tumors.’
Test for evidence of cancer that may be undetectable by current 
standard of care methods1,4
Track up to 200 variants in the blood for optimal personalization6
Within ~4 weeks* for baseline tests and within ~10 days* for monitoring tests, upon sample receipt
Assess risk level and treatment response4 in patients with solid tumors§
Dark gray DNA helixes with an orange circle around one gold helix, and the words ‘For solid tumors.’
Video for health care providers describing molecular residual disease and giving an overview of the Oncodetect MRD test.

Turn insights into action

The tumor-informed Oncodetect Molecular Residual Disease (MRD) test provides clear, quantitative† MRD results on which to base your patient’s treatment decisions. The test report can help guide adjuvant therapy decisions, monitor cancer recurrence, and assess response to treatment.6

Guide adjuvant therapy

Gain insight into your patient’s risk for cancer recurrence or progression.6 Oncodetect MRD test results can help inform the use and intensity of therapy.

Early detection of recurrence

MRD testing can identify recurrence sooner than standard-of-care imaging,1,6 enabling you to intervene earlier, adjust follow-up frequency, and possibly improve patient outcomes.

Therapy response

Assess your patient’s response to therapy through ongoing monitoring, which can help inform the intensity and duration of treatments.

MRD testing can change the course of cancer care throughout the treatment journey2-5

Graph depicting ‘tumor burden’ on the y axis and ‘cancer detectable clinically or radiographically’ on the x axis, showing that MRD testing can: Look for neoadjuvant therapy response, guide adjuvant therapy decisions, monitor for recurrence, and track treatment efficacy.

Highly personalized, highly sensitive6

The Oncodetect MRD test tracks up to 200 variants specific to a patient’s tumor, granting more opportunities to detect ctDNA in the blood.6,7 It also has a low limit of detection of 15 parts per million (0.0015% tumor fraction) with high end inputs, and observed detection down to 2 parts per million seen in clinical validation studies, so it can detect MRD with high sensitivity||6 after surgery or at the early stages of recurrence. To minimize false negatives in most clinical scenarios, the limit of detection should be below 100 PPM (0.01% TF).8
78%

In the post-surgical setting, the Oncodetect MRD test correctly identified 78% of colorectal cancer patients whose cancer would recur.6

94%

In the surveillance setting, the Oncodetect MRD test correctly identified 94% of patients with stage III colorectal cancer whose cancer would not recur.6

91%

In the surveillance setting, the Oncodetect MRD test correctly identified 91% of patients with stage III colorectal cancer whose cancer would recur.6

50x
In the surveillance setting, patients with stage III colorectal cancer with detectable ctDNA identified by the Oncodetect MRD test were 50x more likely to have a recurrence.6
Up to 200 variants

The tumor-informed Oncodetect MRD test analyzes up to 200 variants specific to your patient's cancer to detect even a slight amount of ctDNA.6

The Oncodetect MRD test can detect cancer recurrence more than 2 years earlier than imaging.6

The Oncodetect MRD test provides residual disease detection and monitoring, allowing you and your patient to make more informed treatment decisions.

MRD testing could benefit over 3 million patients—including yours

It’s estimated that 3+ million patients in the United States alone could benefit from MRD testing,‡ and your patient could be one of them. The Oncodetect MRD test can detect and monitor ctDNA levels in the blood of patients with solid tumors,§ allowing you to make treatment decisions with more confidence.
A woman in a headwrap looking off into the distance.

Advancing MRD testing through cutting-edge technology and collaborative research

At Exact Sciences, we’re advancing MRD testing with innovative technologies and rigorous clinical validation. By investing in robust research and building a strong network of clinical collaborations, we are committed to making MRD testing an essential tool in cancer care.
A doctor sitting at a desk looking at a laptop.

Ordering a test for your patients is fast and easy 

Order tests, access results, and receive updates through our Provider Hub.

Have questions?

Call us at +1 866-662-6897.

References and footnotes

  1. Centers for Medicare & Medicaid Services, Medicare Coverage Database. LCD—MolDX: Minimal Residual Disease Testing for Cancer. Accessed January 21, 2025. https://www.cms.gov/
  2. Chakrabarti S, et al. Cancers. 2022;14:3078.
  3. Dasari A, et al. Nat Rev Clin Oncol. 2020;(17):757-770.
  4. Cohen SA, et al. Nature. 2023;619(7969):259-268.
  5. Malla M, et al. J Clin Oncol. 2022;40(24):2846-2857. 
  6. Diergaarde B, Young G, Hall DW, Mazloom A, Costa G, Subramaniam S, Palomares M, Garces J, Baehner FL, Schoen RE; and other members of the Exact Sciences MRD Group. Circulating tumor DNA as a marker of recurrence risk in Stage III colorectal cancer: The α‐CORRECT study. Journal of Surgical Oncology.
  7. Santonja et al. EMBO. 2023. https://www.embopress.org/doi/full/10.15252/emmm.202216505
  8. Everett J. Moding, Barzin Y. Nabet, Ash A. Alizadeh, Maximilian Diehn; Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease. Cancer Discov 1 December 2021; 11 (12): 2968–2986
  9. Estimated turnaround times based on data on file from previous testing, actual turnaround times may vary.
  10. Internal validation data on file.
  11. Internal estimate for addressable patient populations based on solid tumors amenable to MRD testing.
  12. The test has been validated in patients with stage II-IV colorectal cancer and Exact Sciences is currently pursuing applications in additional disease ontologies.
  13. Data on file, additional analysis performed.

    14. This test was developed, and its performance characteristics determined by Genomic Health, Inc. The Oncodetect test was clinically validated in colorectal cancer patients with stage II-IV disease. Performance characteristics may not apply in tumor types not included in this test’s clinical validation. The test has not been cleared or approved by the US Food and Drug Administration. The test has been validated as a Laboratory Developed Test per institutional and applicable CLIA regulation (CLIA# 03D2048606) and College of American Pathology (CAP# 8869063) as qualified to perform high complexity clinical laboratory testing.